Signos Reviews: What the CGM and Signos+ GLP-1 Plan Deliver
By WPG Research Team · Last verified
Signos reviews are mostly positive on the app stores (4.6 on Apple from 1,023 ratings, 4.3 on Google Play from 291), and its own study found about 5% average weight loss at six months. It fits adults who want glucose data. The catch: no refunds on CGM plans, and Signos+ uses compounded, not FDA-approved, GLP-1s.
Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers.
| Question | Short answer |
|---|---|
| What is Signos? | An app plus a Dexcom Stelo glucose sensor, sold as a weight-management program |
| Is it FDA-cleared? | Yes. The Signos Glucose Monitoring System was cleared by FDA (510(k) K250106) on March 21, 2025, for adults 18+ not on insulin |
| Does it prescribe GLP-1s? | Only on the Signos+ plan, through OpenLoop Health clinicians, and only compounded semaglutide or tirzepatide |
| Does it work? | In Signos's own 2026 study, users lost 5.14% of body weight on average at six months; more engaged users lost 5.90% |
| App ratings (Nov 17, 2026) | Apple App Store 4.6 (1,023 ratings); Google Play 4.3 (291 reviews) |
| Price | CGM plans list at $169 to $299 a month; GLP-1 Essentials $89 a month at list ($72 shown November 18, 2026); Signos+ from $199 a month |
| Refunds | CGM plans: all sales final. Signos+: no refund after you cancel, except if a clinician finds you ineligible |
| Who it's not for | People on insulin, on dialysis, with problematic low blood sugar or an active eating disorder; Signos+ also excludes Louisiana and anyone 75 or older |
Bottom line: Signos is a strong pick if you want to see how food, sleep and exercise move your glucose, and if you'll log meals and check the app most days. The study results depend on that engagement. If what you want is the strongest weight-loss medicine, Signos+ is a compounded-GLP-1 program with a CGM attached, and FDA-approved options cost a similar amount elsewhere.
What Signos is, and what it isn't
Signos is a metabolic health app that pairs with the Stelo glucose biosensor made by Dexcom. You wear the sensor on the back of your upper arm for up to 15 days. It reads your glucose every 5 minutes and sends the data to your phone every 15 minutes. The app shows how meals, movement, sleep and stress change your glucose, then suggests what to eat or how to move next.
FDA cleared the Signos Glucose Monitoring System through the 510(k) pathway (K250106) on March 21, 2025, and Signos launched it publicly on August 20, 2025. The cleared use is narrower than the marketing sounds. The FDA summary says the system shows glucose values for people 18 and older not on insulin, helps them understand how diet and exercise affect glucose swings, and that "this information may be useful in helping users to maintain a healthy weight." It's a monitoring device. It isn't an FDA-approved weight-loss treatment.
Signos also sells a prescription program, Signos+. Signos doesn't prescribe anything itself. Its legal notice says that apart from registered dietitians, Signos doesn't employ licensed clinicians, and that clinical care comes from OpenLoop Health and other independent clinician networks.
The three Signos plans
Every plan includes the sensor and the full app. What changes is whether you get medication and how many sensors you get.
| Plan | Who it's for | Price on Nov 17, 2026 | Sensors | Medication |
|---|---|---|---|---|
| Signos CGM | Not on a GLP-1, wants daily glucose data | Lists at $169/mo (6-month), $199/mo (3-month), $299/mo (1-month); shown at $127, $150 and $225 with a 25% site-wide discount | 2 a month, worn continuously | None |
| GLP-1 Essentials | Already on a GLP-1 from any provider | $89/mo for a 6-month program | 6 sensors over 6 months, worn part-time | Not included |
| Signos+ | Wants a GLP-1 prescription plus the app | From $199/mo, 3- or 6-month program | 4 sensors on the 6-month program; 2 on the 12-week plan | Compounded semaglutide or tirzepatide, if a clinician prescribes it |
On November 18, 2026, Signos showed GLP-1 Essentials at $72 a month for six months.
Two details stand out. First, Signos+ includes far fewer sensors than the CGM plan: 4 sensors cover about 60 days of a 24-week program, so you won't have continuous data. Second, Essentials works with any GLP-1, branded or compounded, from any provider, so you don't have to switch prescribers to use it.
For every price, fee and total by plan length, see our Signos cost breakdown.
Signos's plans page shows current prices and the eligibility questions before checkout.
See Signos plans and pricesDoes Signos work? What the study shows
Signos's main evidence is a study published in Diabetes Technology & Therapeutics on June 12, 2026. Researchers looked back at app data from 3,007 adults with a BMI of 30 or higher who didn't have diabetes and weren't taking GLP-1 medicine.
| Measure | Result |
|---|---|
| People in the main analysis | 3,007 adults, BMI 30+, no diabetes, no GLP-1 |
| Weight loss per week while engaged with the app | 1.17% |
| Weight loss per week while not engaged | 0.44% |
| People with 180-day weight data | 1,147 |
| Average weight loss at 180 days | 5.14% |
| Higher-engagement group at 180 days | 5.90% (vs 4.38% in the lower-engagement group) |
| Highly engaged people with BMI 40+ | 7.09% |
"Engaged" meant doing things in the app, like logging meals and exercise or opening insights. Wearing the sensor alone didn't count.
Read these numbers with three limits in mind:
- It's observational. It shows that engagement and weight loss went together. It doesn't prove the app caused the loss. People who log every meal may be more motivated in other ways too.
- Most people dropped out of the six-month numbers. The AJMC write-up notes the 180-day analysis covered only 38.1% of the eligible group, which can make results look better than average.
- Medication wasn't tracked closely. People on GLP-1s were excluded at the start, but the authors didn't systematically track later medication use.
For scale: 5% to 6% loss at six months is real and clinically meaningful. It's well below what GLP-1 medicines produced in their main trials: about 15% for semaglutide 2.4 mg at 68 weeks in STEP 1, and about 21% at tirzepatide's top dose at 72 weeks in SURMOUNT-1. Signos+ is the company's answer to that gap, but no published study covers Signos+ itself.
What Signos ratings and reviews say
These are the ratings we could open on November 17, 2026:
| Where | Rating | Number of reviews | Notes |
|---|---|---|---|
| Apple App Store (Signos app) | 4.6 out of 5 | 1,023 ratings | Rates the app, not the medication program |
| Google Play (Signos app) | 4.3 out of 5 | 291 reviews | Rates the app |
| Signos's own reviews page | 4.8 out of 5 | 256 reviews | Hosted and collected by Signos |
We couldn't load Signos's Trustpilot or Better Business Bureau pages on the day we checked, so we don't report those scores here. App ratings mostly reflect the app experience, not the Signos+ medication program, which runs through OpenLoop Health.
Signos's own fine print gives a clear view of where friction can come from:
- Sensors can fail early. Signos's own footnote says 77.9% of sensors lasted the full 15 days in testing. About 20% may not, and some of those last under 12 days. Signos says it will try to replace sensors the manufacturer confirms as failures.
- No refunds on CGM plans. The plans page says "All sales final. No refunds or exchanges." The terms add that once an order ships, it's not refundable.
- Auto-renewal. CGM plans renew for the same length unless you cancel in the app at least 24 hours before your term ends. Cancelling doesn't give a prorated refund, and the terms say an early cancellation fee may apply within an active term.
- Signos+ billing. You must ask to cancel at least 72 hours before your billing date or you'll be charged once more. Refunds after cancelling aren't offered, except when an OpenLoop clinician finds you medically ineligible.
- Arbitration. Disputes go to binding arbitration through JAMS, and you give up class actions.
Who Signos fits, and who should skip it
| Signos is a good fit if you | Look elsewhere if you |
|---|---|
| Want to see how specific meals, sleep and stress move your glucose | Take insulin or have problematic low blood sugar |
| Will log meals and check the app most days | Are on dialysis or have an active eating disorder |
| Are on a GLP-1 already and want to track fat vs lean loss (Essentials) | Want an FDA-approved GLP-1 (Signos+ prescribes compounded only) |
| Like paying with HSA or FSA funds, if your plan allows it | Live in Louisiana or are 75 or older (Signos+ age limit is 18 to 74) |
| Can commit to 3 or 6 months, since short plans cost the most | Want the option of a refund if it isn't for you |
Signos+ also asks for a video visit if you live in Arkansas, Delaware, Kansas, Mississippi, New Mexico, Rhode Island, West Virginia or Washington, DC. Nebraska requires you to be 19 or older.
If Signos+ sounds right, the intake starts with a short quiz, and Signos says it issues a full refund if a clinician finds you ineligible.
Check if Signos+ fits youSignos+ vs a GLP-1 program on its own
Signos says Signos+ costs "the same price as medication alone." Here's how its starting price compares with two other programs we checked the same day:
| Program | Medication | Starting price | What's included |
|---|---|---|---|
| Signos+ | Compounded semaglutide or tirzepatide (not FDA-approved) | From $199/mo, 3- or 6-month program | Medication, clinician care via OpenLoop, 2 or 4 CGM sensors, app, nutritionist support |
| Arbor | Compounded semaglutide or tirzepatide (not FDA-approved) | Semaglutide from $89/mo on a 12-month prepaid plan ($179 month-to-month); tirzepatide from $119/mo ($249 month-to-month) | Medication, clinician care via MD Integrations, dietitian support; no CGM |
| Ro | FDA-approved GLP-1s (Wegovy, Zepbound, Foundayo and others) | Membership $39 first month, then $74 to $149/mo, plus medication (Wegovy pill from $149/mo, Zepbound KwikPen from $299/mo) | Membership and clinician care; medication billed separately |
So Signos+ isn't the cheapest compounded GLP-1. Arbor's longer plans cost less per month. What Signos+ adds is the CGM and app. Whether that's worth paying for depends on whether you'll use the glucose data. If your priority is an FDA-approved medicine, Ro and other brand-name programs fit better.
The FDA notes that compounded drugs aren't FDA-approved and aren't reviewed by FDA for safety, effectiveness or quality. Signos and Arbor both say this on their own sites. Our guide to whether compounded semaglutide is safe covers the trade-offs.
Not sure whether you need a CGM, a compounded GLP-1 or a brand-name one? Find My GLP-1 Path compares routes by budget and goal.
Compare GLP-1 programs for youUsing Signos alongside a GLP-1 you already take
GLP-1 Essentials is the plan built for this. It's $89 a month at list price for six months ($72 shown November 18, 2026), includes six 15-day sensors to wear at the times you choose, and logs your doses. Signos says it works with semaglutide or tirzepatide, branded or compounded, from any provider, and that you don't need a new prescription.
The main use is tracking whether you're losing fat or muscle and building habits for when the medicine stops. Losing lean mass is a known GLP-1 issue; our guide to preventing muscle loss on GLP-1s covers protein and strength training. If you're planning for life after medication, see our GLP-1 maintenance programs guide.
One caution from Signos's own label: don't change any medication based on your sensor readings without talking to your clinician.
Could you get the same thing for less?
You can buy the Stelo sensor without Signos. Dexcom sells it directly for $99 for a one-month supply of 2 sensors, $89 a month on a monthly subscription, or $252 every 3 months. That gets you the sensor and Dexcom's own app, but not Signos's meal predictions, movement prompts, body scans or dietitian chat.
At list price, the Signos 6-month CGM plan is $169 a month, so the Signos app and support cost about $80 a month more than Stelo's monthly subscription (our math from both sites' prices on November 17, 2026). With Signos's 25% discount showing that day ($127 a month), the gap was about $38.
FAQ
Are Signos reviews good?
Mostly. On November 17, 2026, the Signos app had 4.6 out of 5 on the Apple App Store from 1,023 ratings and 4.3 on Google Play from 291 reviews. Signos's own site shows 4.8 from 256 reviews. App ratings reflect the app more than the Signos+ medication program.
Does Signos work for weight loss?
In a 2026 study of Signos users without diabetes and not on GLP-1s, average weight loss was 5.14% at six months, and 5.90% for more engaged users. The study was observational and only 38.1% of eligible users had six-month data, so it shows an association, not proof.
Is Signos FDA-approved?
The Signos Glucose Monitoring System is FDA-cleared, not approved: it went through the 510(k) pathway (K250106) on March 21, 2025. The compounded GLP-1s offered through Signos+ aren't FDA-approved.
Does Signos prescribe GLP-1s?
Only through Signos+. OpenLoop Health clinicians decide whether to prescribe, and the only options are compounded semaglutide and compounded tirzepatide. The standard CGM plan and GLP-1 Essentials don't include medication or a prescription.
Can I get a refund from Signos?
CGM plans are "all sales final" with no refunds or exchanges. For Signos+, you get a full refund if a clinician finds you ineligible; otherwise, cancelling doesn't bring a refund. Ask to cancel Signos+ at least 72 hours before your billing date.
Does Signos take insurance or HSA/FSA?
Signos sells directly without insurance. It says HSA or FSA payment is possible depending on your account administrator, and that it isn't responsible for reimbursement. The full breakdown is in our Signos cost guide.
Can I use Signos if I have diabetes?
Signos says it isn't right for people who take insulin, have problematic low blood sugar or need a prescription CGM to manage diabetes. Other people with diabetes should ask their clinician first.
Who is Signos+ not available to?
Signos+ isn't available in Louisiana, and the general age range is 18 to 74 (19+ in Nebraska). People in Arkansas, Delaware, Kansas, Mississippi, New Mexico, Rhode Island, West Virginia and Washington, DC need a video visit.
How long does a Signos sensor last?
Each Stelo sensor is made to last 15 days. Signos's footnote says 77.9% of sensors lasted the full 15 days in testing, so about 1 in 5 may end early.
Is Signos worth it if I'm already on a GLP-1?
It can be if you want to track fat vs lean loss and build habits before stopping the medicine. GLP-1 Essentials is $89 a month at list price for six months ($72 shown November 18, 2026), works with any GLP-1 and doesn't need a new prescription.
What we verified
- Signos plan prices, sensor counts, eligibility questions and refund wording on signos.com/plans, /essentials and /lp/signos-plus, and the checkout store's 6-month plan listing, November 17, 2026; GLP-1 Essentials price rechecked November 18, 2026
- Signos+ medication, states, age range and clinician partner on signos.com/lp/signos-plus, November 17, 2026
- Cancellation, auto-renewal, refund and arbitration terms in Signos's terms and conditions, November 17, 2026
- FDA 510(k) K250106 decision record and decision summary
- The Diabetes Technology & Therapeutics study abstract (June 12, 2026) and the AJMC summary of its limits
- App Store and Google Play ratings, November 17, 2026
- Dexcom Stelo, Arbor and Ro prices on their own pricing pages, November 17, 2026
- Not verified: Trustpilot and BBB pages for Signos would not load for us; we don't report those scores. Signos doesn't show Signos+ prices by medication or dose before its intake quiz.
We don't use testimonials or before-and-after photos. See our editorial standards and how we rank providers.
Sources
- Signos: plans and pricing (signos.com/plans)
- Signos: GLP-1 Essentials (signos.com/essentials)
- Signos+: GLP-1 plus CGM program (signos.com/lp/signos-plus)
- Signos: CGM and sensor details (signos.com/cgm)
- Signos: terms and conditions (signos.com/terms-conditions)
- Signos: member reviews page (signos.com/reviews)
- Signos Help Center: About Signos+
- FDA 510(k) K250106: Signos Glucose Monitoring System
- FDA 510(k) decision summary K250106
- Diabetes Technology & Therapeutics: engagement with an AI- and CGM-integrated platform and weight loss, June 2026
- AJMC: AI-CGM platform engagement linked to clinically meaningful weight loss
- Apple App Store: Signos
- Google Play: Signos
- Dexcom Stelo: buy
- Impact of semaglutide on body composition: STEP 1 exploratory analysis
- Body composition changes with tirzepatide in SURMOUNT-1
- FDA: concerns with unapproved GLP-1 drugs used for weight loss
- Arbor: GLP-1 plans and pricing (startarbor.com)
- Ro: weight loss pricing (ro.co/weight-loss/pricing)
Still deciding between a CGM, a compounded GLP-1 and a brand-name one? Take our free Find My GLP-1 Path quiz. It takes about 2 minutes, and there's no signup.
Find My GLP-1 Path